Erasca appoints Charles Fuchs as president of R&D

Reuters2026/08/10 12:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Erasca named Charles S. Fuchs president of research and development, effective immediately.
Fuchs most recently served as chief medical officer at Tubulis, where he led clinical strategy and pipeline development.
He previously held senior oncology drug development roles at Genentech and Roche, following earlier leadership posts at Yale Cancer Center and Dana-Farber.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806331) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Erasca appoints Charles Fuchs as president of R&D

You may also like

Crypto prices